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Approximately 10% of all melanomas occur in subjects 
with a family history of melanoma. This retrospective 
follow-up study investigated the characteristics of pa-
tients with familial melanoma who made unscheduled 
visits to our pigmented lesions clinic, and the diagno-
sis of excised lesions. A total of 110 (9%) out of 1,267 
patients made at least one unscheduled visit between 
May 2011 and February 2016. Histopathology was ta-
ken from 59 patients. Thirty-four naevi, 7 melanomas 
and 3 basal cell carcinomas were detected. All patients 
with melanoma were CDKN2A carriers and all mela-
nomas were discovered at a very early stage. In this 
patient population it appears to be safe to limit visits 
to once or twice yearly, provided patients are easily 
able to make an unscheduled extra visit if they have a 
worrisome lesion. We recommend supporting patients’ 
self-reliance by stimulating them to carry out self-exa-
mination of their skin.
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Familial aggregation of melanomas is reported to oc-cur in approximately 5–10% of all melanomas (1). 
In up to 40% of these families a mutation is present in 
the high penetrance melanoma susceptibility gene CD-
KN2A (2). In the Netherlands, the most prevalent CD-
KN2A germline mutation is a specific founder mutation 
(c.225-243del19), known as the p16-Leiden mutation 
(3). The second known mutation is found on the CDK4 
gene on chromosome 12, which occurs in approxima-
tely 3% of melanoma families (4). Reports on the mean 
age of diagnosis of the first melanoma in these families 
range from 33–36 years in patients with CDKN2A gene 
mutation, to 41–45 years in patients without a CDKN2A 
gene mutation (with an unknown mutation) (2, 5, 6). In 
patients with a CDKN2A mutation the lifetime risk for 
developing melanoma is 70% at the age of 80 years, with 
a 30% chance of developing multiple melanomas (5, 7).
The Leiden University Medical Center is a tertiary 
referral centre for (familial) melanoma, where the first 
surveillance programme for familial melanoma was ini-
tiated in 1981. Family members at high risk of developing 
melanoma visit the pigmented lesions clinic (PLC) for a 
total skin examination at least once a year. 
It is not known what proportion of patients return 
for an unscheduled visit and what the characteristics 
of these patients are. Moreover, it is not known if these 
visits lead to the discovery of melanomas. To investigate 
these questions, patients’ characteristics and pathology 
outcomes for high-risk family members who paid at least 
one interval visit during the period of the study were 
analysed. It was hypothesized that younger patients and 
those who were carriers of a gene mutation would return 
for an unscheduled visit more often. In addition, it was 
hypothesized that most patients would present with a 
lesion on the front of the body, due to its visibility. 
METHODS
This retrospective study investigated the clinical and histological 
characteristics of patients who had paid one or more unscheduled 
visit to the PLC of the Department of Dermatolog, Leiden Uni-
versity Medical Centre (LUMC), Leiden, the Netherlands, over 
a 5-year period. 
Set up of pigmented lesions clinic
Patients at high risk of developing melanoma visit the PLC for 
a total skin examination at least once a year. Like all other pa-
tients who visit the PLC they repeatedly receive information and 
practical tips on how to perform adequate skin self-examination, 
including instructions on how to use 2 mirrors to examine their 
back, or to ask their partner to assist with the skin check. Patients 
are also instructed to make unscheduled visits whenever they are 
worried about a particular lesion.
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SIGNIFICANCE
This study investigated if patients with a high risk for me-
lanoma who visited a pigmented lesion clinic at least once 
per year also returned for unscheduled visits and we report 
on the lesions that were found. Nine percent of the patients 
came for an unscheduled visit and 7 early melanomas were 
found in carriers of a high risk mutation for melanoma. 
In this population it  is safe to limit regular visits to once 
or twice yearly, as long as patients get instructions for skin 
self-examination and have readily access to pay an extra 
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Study population
The study period was May 2011 to February 2016 and, during this 
period, patients were routinely scheduled once a year. Eligible 
patients were 12 years old and over and had an indication for 
screening at this clinic: they carried a CDKN2A or CDK4 muta-
tion; had 25% and 50% chance of being a CDKN2A/CDK4 carrier, 
or were part of a family with an unknown mutation (defined as 3 
melanoma cases in a family in which no CDKN2A/CDK4 muta-
tion was found). Patients were included in the study when they 
attended the clinic for an unscheduled visit, made at the request 
of the patient, in between annual visits. Patients were excluded 
if the reason for their visit was unrelated to pigmented lesions. 
Digital medical charts were used to obtain information on the 
age and sex of patients, gene mutation status, the reason for the 
interval visit, and histology reports if an excision was performed 
after the interval visit. 
Descriptive statistics were performed using IBM SPSS Sta-
tistics 23. 
RESULTS
During the study period 1,267 patients visited the PLC at 
the LUMC at least once a year for a scheduled follow-up. 
Of these, 544 patients (43%) were male, with a mean age 
of 39 years (range 1–86 years) and 110 patients (9%) paid 
at least one unscheduled visit, of whom 34% were male 
with a mean age of 45 years (range 13–78 years) (Table 
I). The majority (77%) made only one unscheduled visit. 
Of 59 patients, histology was most often taken from the 
trunk (front and back) and the leg. Of these 59 patients 
22 carried a CDKN2A mutation, 22 had a 50% chance 
of being a CDKN2A mutation carrier, 7 were carriers 
of an unknown mutation, 6 had familial melanoma (2 
melanoma cases) with unknown mutation, and 2 had a 
25% chance of being a CDKN2A carrier.
A melanoma was found in 7 patients; one in situ mela-
noma and 6 invasive. Table II shows the characteristics 
of patients who were diagnosed with a melanoma at 
the unscheduled visit. Three patients were male, ages 
ranged from 37 to 67 years. All 7 patients were CDKN2A-
mutation carriers, and all have had at least one cutaneous 
melanoma in the past. All melanomas were indicated by 
the patients. 
DISCUSSION
This study analysed the characteristics of patients with 
familial melanoma who returned for an unscheduled 
visit. Women made more unscheduled visits than men, 
which could be because they are more likely to visit 
the doctor earlier when they are worried. Furthermore, 
women perform skin self-examination more frequently 
or more accurately than men and therefore discover chan-
ging lesions earlier. Mesters et al. (8) found that 59% of 
patients who performed adequate skin self-examination 
were female. In the current study the most patients were 
between 40 and 59 years of age. This might be explai-
ned by the assumption that younger people are busier in 
general and have less time to perform a thorough self-
Table I. Characteristics of patients with unscheduled visits
Characteristics of patients with ≥1 unscheduled visit n (%)
Sex
  Male 34 (31)
  Female 76 (69)
Age
  12–19 years   6 (5.5)
  20–39 years 31 (28)
  40–59 years 45 (41)
  > 60 years 28 (25.5)
Mutation status
  CDKN2A carrier 49 (44)
  50% chance of CDKN2A 35 (32)
  25% chance of CDKN2A   2 (2)
Familial melanoma (3 melanoma cases) with unknown mutation 18 (16)
Familial melanoma (2 melanoma cases) with unknown mutation   6 (6)
Histology – outcome
  Melanoma   7 (6)
  Basal cell carcinoma   3 (3)
  Squamous cell carcinoma   0 (0)
  Common naevus 22 (20)
  Dysplastic naevus 12 (11)
  Other benign 15 (14)
  No histology 51 (46)
Number of histology taken/person
  0 51 (46)
  1 44 (40)
  2   8 (7)
  3   5 (5)
  4   2 (2)
Number interval visit/person
  1 85 (77)
  2 19 (17)
  3   2 (2)
  4   4 (4)
Location histology
  Scalp   3 (4)
  Face 12 (15)
  Neck   7 (9)
  Upper arm/shoulder 11 (13)
  Underarm   4 (5)
  Trunk (front side) 13 (16)
  Trunk (back side) 16 (20)
  Buttock   1 (1)
  Leg 14 (17)










1 59 years M CDKN2A Metastases Change T1b (0.7 mm) Neck 1 1
2 37 years F CDKN2A 1 Change T1a (0.3 mm) Upper leg 1 1
3 41 years M CDKN2A 1 Change T1a (0.42) Trunk (back side) 1 1
4 48 years F CDKN2A 7 Change Melanoma in situ Trunk (front side) 4 4
5 55 years F CDKN2A 4 Change T1a (0.4 mm) Upper arm 1 1
6 53 years F CDKN2A 1 New lesion T1b (0.78 mm) Upper leg 1 1
























































669Evaluation of unscheduled visits of patients with familial melanoma
Acta Derm Venereol 2018
examination or schedule an appointment. On the other 
hand, patients with hereditary melanomas are more likely 
to be diagnosed with their first melanoma at an earlier 
age and, for this reason, they may be more cautious and 
alert (9). A possible explanation for people over 60 years 
of age in the current study being less frequent visitors 
might be that this group was relatively small.
During unscheduled visits histopathology was ta-
ken most frequently from patients with a 50% chance 
of being a CDKN2A-mutation carrier or from proven 
CDKN2A-mutation carriers. This may be due to doctors 
being extra alert and cautious when there is a higher a 
priori chance of a melanoma, or to these patients being 
extra cautious themselves and insisting on excision, or 
to a combination of both. 
A surprising finding of our study was that most patho-
logy was taken from the back. Because of the difficulty of 
examining the back, compared with the legs or the front 
of the body, we expected this to be the area that patients 
examined the least. However, repeated extensive skin 
self-examination instruction might be the reason why 
lesions on the back were presented frequently during an 
unscheduled visit. The value of adequate instruction for 
finding melanoma at an early stage has been shown by 
many studies (10–17).
At our PLC there was a 12% chance of having a 
melanoma diagnosed during an unscheduled visit when 
histology was taken. All patients with melanoma during 
an unscheduled visit (Table II) had had at least one mela-
noma in the past and indicated the melanoma themselves. 
The previous melanoma might have made them more 
alert to recognize a suspicious lesion. 
All melanomas found on unscheduled visits were thin 
melanomas, which is in agreement with other studies 
(18–20). Whether this is a result of improved surveil-
lance or biological factors, such as the higher proportion 
of slow-growing superficial spreading melanoma in this 
population, or a combination of both, is not known. In 
an earlier study we found that tumour thickness did not 
correlate with the length of the screening interval for 
intervals less than 24 months. However, non-compliance 
with screening resulted in significantly thicker melano-
mas with a potentially worse outcome (7). Worldwide, 
members of melanoma families are offered much more 
frequent screenings, of up to 4 times a year. In a recent 
review screening frequencies ranging from every 3 to 12 
months were advised with higher frequencies for indivi-
duals with high numbers of atypical naevi (21). Until re-
cently (January 2016) we offered regular screenings to all 
members of melanoma families only once a year. Despite 
less frequent screening the mean Breslow thickness of 
melanoma in our patients with hereditary melanomas was 
approximately 0.5 mm, which is comparable to the results 
found with more frequent screening elsewhere (22, 23). 
This is probably the case because, from the beginning 
of our PLC in 1981, we have invested a lot of effort in 
instruction for skin self-examination and have offered 
patients unlimited and quickly scheduled appointments 
to return earlier in case of worrisome skin lesions. 
Study limitations
This study has some limitations. The detailed charac-
teristics of patients paying an unscheduled visit were 
examined. Ideally, this group would have been compared 
with the total population with familial melanoma in our 
PLC who did not pay an interval visit. This would also 
have enabled us to compare the proportion of screen 
melanomas with the proportion of melanomas found at 
unscheduled visits. In a retrospective study we found that 
only approximately half of all melanomas were detected 
at regular screening appointments (7). Other limitations 
were the low number of melanoma events in the study 
period and the fact that no information was available 
about lesions that were not excised.
Conclusion
Of the whole familial melanoma population of our 
PLC, 9% paid at least one unscheduled visit during the 
5-year study period. Most patients were from CDKN2A-
mutation-positive families, with only very early stage 
melanomas found during these unscheduled visits. We 
highly recommend encouraging patients with familial 
melanoma to perform skin self-examination and to ini-
tiate unscheduled visits if they are worried about a lesion.
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